Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.

Date publication

septembre 2016

Journal

Arthritis & rheumatology (Hoboken, N.J.)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEVILLIERS Hervé , Pr BONNIAUD Philippe

Tous les auteurs :
Jachiet M, Samson M, Cottin V, Kahn JE, Le Guenno G, Bonniaud P, Devilliers H, Bouillet L, Gondouin A, Makhlouf F, Meaux-Ruault N, Gil H, Bienvenu B, Coste A, Groh M, Giraud V, Dominique S, Godeau B, Puéchal X, Khouatra C, Ruivard M, Le Jeunne C, Mouthon L, Guillevin L, Terrier B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26946346

Résumé

To describe the efficacy and safety of omalizumab, an anti-IgE monoclonal antibody, in patients with refractory and/or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA).

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Anti-Allergic Agents, therapeutic use, Asthma, complications, Churg-Strauss Syndrome, complications, Female, Humans, Male, Middle Aged, Omalizumab, adverse effects, Recurrence, Remission Induction, Retrospective Studies, Treatment Outcome, Young Adult